Evaxion Biotech A-S American Depositary Receipt Repr 1 Sh News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.11.22	Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02 (GlobeNewswire)
14.11.22	Evaxion CEO kommentiert strategische Ausrichtung (GlobeNewswire)
10.11.22	Evaxion CEO comments on strategic focus (GlobeNewswire)
06.10.22	Evaxion begrüsst Per Norlén als neuen CEO (GlobeNewswire)
05.10.22	Evaxion welcomes Per Norlén as new CEO. (GlobeNewswire)
22.09.22	Pre-market Movers: PRST, KOD, GRVY, BEAT, PULM… (RTTNews)
21.09.22	Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy (GlobeNewswire)
06.09.22	Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School (GlobeNewswire)
10.08.22	Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
02.08.22	Evaxion Biotech A/S Announces Executive Management Changes (GlobeNewswire)
29.07.22	Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10 (GlobeNewswire)
30.06.22	Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target (GlobeNewswire)
23.06.22	Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer (GlobeNewswire)
07.06.22	Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital (GlobeNewswire)
11.05.22	Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
10.05.22	Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02 (GlobeNewswire)
29.04.22	Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11 (GlobeNewswire)
06.04.22	Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies (GlobeNewswire)
22.03.22	Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
14.03.22	Evaxion Biotech Strengthens Management Team with Two Senior Appointments (GlobeNewswire)
07.03.22	Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02 (GlobeNewswire)
26.01.22	Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck (GlobeNewswire)
18.01.22	Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma (GlobeNewswire)
09.11.21	Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares (GlobeNewswire)
09.11.21	Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update (GlobeNewswire)
05.11.21	Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering (GlobeNewswire)
05.11.21	Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON… (RTTNews)
04.11.21	Pre-market Movers: EVAX, PETZ, BTTX, QNST, FATBB… (RTTNews)
26.10.21	Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital (GlobeNewswire)
25.10.21	Evaxion Announces Collaboration With Merck & Co. To Evaluate EVX-01 With KEYTRUDA (RTTNews)
25.10.21	Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma (GlobeNewswire)
14.10.21	Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award (GlobeNewswire)
12.10.21	Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021 (GlobeNewswire)
21.09.21	Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer (GlobeNewswire)
02.09.21	Pre-market Movers: FCUV, TLSA, ZSAN, METX, ASMB… (RTTNews)
03.06.21	Evaxion Biotech Aims To Develop Next Generation Of Corona Virus Vaccines (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	77.34	3.26 %	K V
CieFinRichemont	138.30	3.02 %	K V
UBS Group	28.99	1.86 %	K V
Sika	216.60	1.74 %	K V
Part Grp Hldg	1’262.50	1.36 %	K V
Swiss Life Hldg	707.00	-0.79 %	K V
Swiss Re	131.45	-0.94 %	K V
Sonova Hldg	292.60	-1.28 %	K V
Nestle	73.32	-1.85 %	K V
Givaudan	3’856.00	-2.26 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Evaxion Biotech A-S American Depositary Receipt Repr 1 Sh

Aktien Top/Flop

Meistgelesene Nachrichten